Overview

Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Astra Zeneca, Bristol-Myers Squibb
Treatments:
Dapagliflozin
Insulin